EndoTAG-1

EndoTAG-1 is a novel formulation of paclitaxel encapsulated in positively charged lipid-based complexes (liposomes). This design targets the drug to newly formed tumor blood vessels by exploiting the negative charge of activated endothelial cells involved in tumor angiogenesis. The positive charge on the liposomes facilitates selective accumulation at these sites. Once localized, paclitaxel is released via endocytosis to inhibit cell division and induce apoptosis in proliferating endothelial cells, thereby disrupting tumor vascularization and inhibiting tumor growth. The approach aims to "starve" tumors by selectively attacking their blood supply while sparing normal vasculature. Developed for cancers such as pancreatic cancer and triple-negative breast cancer, EndoTAG-1 has shown activity both as monotherapy and in combination with other agents like paclitaxel or gemcitabine[2][4][5][7].

Brand names

EndoTAG-1EndoTAG1EndoTAG 1EndoTAG™-1SB05-EndoTAG-1SB-05-EndoTAG-1SB 05-EndoTAG-1

Other names

Paclitaxel liposomal (EndoTAG technology)